Ovarian teratoma

Summary

Ovarian teratoma (MONDO:0005602) is a disease and 2 clinical trials. A subtype of gonadal teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian teratoma
Mondo ID	MONDO:0005602
EFO	EFO:0006463
DOID	DOID:5567
ICD-11	1752240825
NCIT	C8110
SNOMED CT	716077006
UMLS	C0280131
MedGen	76072
GARD	0024209
Is cancer (heuristic)	no

Also known as: germ cell teratoma of ovary · germ cell teratoma of the ovary · ovarian germ cell teratoma · ovarian teratoma · teratoma of ovary · teratoma of the ovary

Data availability: 2 cell lines.

Disease family

This is a subtype of gonadal teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › gonadal teratoma › ovarian teratoma

Subtypes (3): ovarian monodermal teratoma, childhood teratoma of the ovary, ovarian biphasic or triphasic teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings